Abstract:Since December 2019, the new SARS-CoV-2-related COVID-19 disease has caused a global pandemic and shut down the public life worldwide. Several proteins have emerged as potential therapeutic targets for drug development, and we sought out to review the commercially available and marketed SARS-CoV-2-targeted libraries ready for high-throughput virtual screening (HTVS). We evaluated the SARS-CoV-2-targeted, protease-inhibitor-focused and protein–protein-interaction-inhibitor-focused libraries to gain a better understanding of how these libraries were designed. The most common were ligand- and structure-based approaches, along with various filtering steps, using molecular descriptors. Often, these methods were combined to obtain the final library. We recognized the abundance of targeted libraries offered and complimented by the inclusion of analytical data; however, serious concerns had to be raised. Namely, vendors lack the information on the library design and the references to the primary literature. Few references to active compounds were also provided when using the ligand-based design and usually only protein classes or a general panel of targets were listed, along with a general reference to the methods, such as molecular docking for the structure-based design. No receptor data, docking protocols or even references to the applied molecular docking software (or other HTVS software), and no pharmacophore or filter design details were given. No detailed functional group or chemical space analyses were reported, and no specific orientation of the libraries toward the design of covalent or noncovalent inhibitors could be observed. All libraries contained pan-assay interference compounds (PAINS), rapid elimination of swill compounds (REOS) and aggregators, as well as focused on the drug-like model, with the majority of compounds possessing their molecular mass around 500 g/mol. These facts do not bode well for the use of the reviewed libraries in drug design and lend themselves to commercial drug companies to focus on and improve.

High-Affinity Peptides for Target Protein Screened in Ultralarge Virtual Libraries

Virus-Derived Peptides for Clinical Applications

Virtual Screening Expands the Non-Natural Amino Acid Palette for Peptide Optimization

Improved genome-scale multi-target virtual screening via a novel collaborative filtering approach to cold-start problem

Process Automation Toward Ultra-High-Throughput Screening of Combinatorial One-Bead-One-Compound (OBOC) Peptide Libraries

Commercial SARS-CoV-2 Targeted, Protease Inhibitor Focused and Protein–Protein Interaction Inhibitor Focused Molecular Libraries for Virtual Screening and Drug Design

Rapid Screening of Peptide Probes Through in Situ Single-Bead Sequencing Microarray.

High-throughput screening normalized to biological response: application to antiviral drug discovery

Virtual Screening on Natural Products for Discovering Active Compounds and Target Information

Improved design and screening of high bioactivity peptides for drug discovery

A Preliminary Study on the Possibility of Screening Small Peptide in Peptide Library

Discovery of Highly Bioactive Peptides through Hierarchical Structural Information and Molecular Dynamics Simulations

Ultra‐Large Virtual Screening: Definition, Recent Advances, and Challenges in Drug Design

A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor

Structure-Based Virtual Screening of Chemical Libraries for Drug Discovery

Identifying high-affinity aptamer ligands with defined cross-reactivity using high-throughput guided systematic evolution of ligands by exponential enrichment

Deep Learning-Based Bioactive Therapeutic Peptide Generation and Screening

Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platform

An Alternating Elution Strategy for Screening High Affinity Peptides from a Phage Display Peptide Library

A Tag‐Free Platform for Synthesis and Screening of Cyclic Peptide Libraries

Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning